This is a definitive win for VTRS — the Federal Circuit's affirmance is the final word on patent infringement for this ANDA. Expect VTRS to receive FDA approval for its generic epoprostenol and launch imminently, capturing share in a branded market. Monitor FDA approval status and launch timing. The stock should re-rate upward as this multi-year patent risk is fully resolved.
Price Chart
Executive Summary
The Federal Circuit affirmed the district court's ruling that Mylan Pharmaceuticals does not infringe Actelion's patents covering epoprostenol (Veletri®). The court upheld the construction that 'pH of 13 or higher' means measured at standard temperature (25±2°C), and Mylan's refrigerated bulk solution—with pH below 12.98 at that temperature—does not literally infringe. Actelion's doctrine-of-equivalents arguments were also barred by prosecution history estoppel and disclosure-dedication rules. This removes a material patent risk for VTRS, clearing the path for its generic epoprostenol ANDA.
Court Ruling Details
Key Facts
- Federal Circuit affirmed non-infringement of Actelion's '802 and '227 patents covering epoprostenol (Veletri®) by Mylan's ANDA product
- Court upheld construction that 'pH of 13 or higher' refers to measurement at standard temperature (25±2°C), not at refrigerated operating temperature
- Mylan's bulk solution undisputedly has pH well below 12.98 at standard temperature — no literal infringement
- Doctrine-of-equivalents claims barred by both prosecution history estoppel (amendment from pH >12 to pH ≥13) and disclosure-dedication rule (specification disclosed pH 12-13 ranges but did not claim them)
- Ruling is final and not subject to further appeal (Federal Circuit is the appellate court for patent cases from district courts)
Financial Impact
Removes patent risk blocking Mylan's generic epoprostenol ANDA. Veletri® is Actelion's (now Johnson & Johnson) product; Mylan's generic would compete in a market with estimated annual U.S. sales in the hundreds of millions. No damages awarded against VTRS.
Risk Factors
- FDA could still delay or deny ANDA approval on non-patent grounds
- Actelion/Johnson & Johnson could seek Supreme Court certiorari (unlikely given no circuit split or novel legal question)
- Generic launch may face pricing pressure or supply constraints
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3lnulh2x-VTRS |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | 8-K | $16.29 $16.94 | ▲ +3.99% | ▲ +3.39% | $17.60 (+8.04%) |
Jun 25, 2026 14w ago | 144 | $16.33 $17.28 | ▲ +5.82% | ▲ +4.56% | $17.60 (+7.78%) |
Jun 18, 2026 15w ago | 8-K | $15.38 $17.29 | ▲ +12.42% | ▲ +12.57% | $17.60 (+14.43%) |
Jun 15, 2026 15w ago | 8-K | $16.04 $16.31 | ▲ +1.68% | ▲ +1.48% | $17.60 (+9.73%) |
May 13, 2026 20w ago | Court Ruling | $17.37 $16.31 | ▼ −6.10% | ▼ −5.49% | $17.60 (+1.32%) |
May 7, 2026 21w ago | 8-K | $17.39 $15.56 | ▼ −10.52% | ▼ −13.66% | $17.60 (+1.21%) |
May 4, 2026 21w ago | 8-K | $15.52 $15.69 | ▲ +1.10% | ▼ −3.86% | $17.60 (+13.40%) |
May 4, 2026 21w ago | Court Ruling | $15.20 $15.69 | ▲ +3.22% | ▼ −2.56% | $17.60 (+15.79%) |
May 4, 2026 21w ago | Court Ruling | $15.20 $15.69 | ▲ +3.22% | ▼ −2.56% | $17.60 (+15.79%) |
Apr 13, 2026 24w ago | Court Ruling | $13.83 $16.92 | ▲ +22.34% | ▲ +14.59% | $17.60 (+27.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access